$269.73
0.13% today
NYSE, Oct 15, 10:00 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$270.07
-1.12 0.41% 1M
+55.54 25.89% 6M
+41.38 18.09% YTD
+29.36 12.20% 1Y
+58.32 27.54% 3Y
+92.26 51.89% 5Y
+214.82 388.81% 10Y
+251.25 1,334.63% 20Y
NYSE, Closing price Tue, Oct 14 2025
-2.94 1.08%

Key metrics

Basic
Market capitalization
$39.4b
Enterprise Value
$38.9b
Net debt
positive
Cash
$1.2b
Shares outstanding
146.4m
Valuation (TTM | estimate)
P/E
28.4 | 24.7
P/S
7.7 | 7.0
EV/Sales
7.6 | 6.9
EV/FCF
23.5
P/B
6.6
Dividends
DPS
$2.12
Yield 1Y | 5Y
0.8% | 0.8%
Growth 1Y | 5Y
10.4% | 6.3%
Payout 1Y | 3Y
22.3% | 25.8%
Increased
4 Years
Financials (TTM | estimate)
Revenue
$5.1b | $5.7b
EBITDA
$1.7b | $2.2b
EBIT
$1.7b | $2.0b
Net Income
$1.4b | $1.6b
Free Cash Flow
$1.7b
Growth (TTM | estimate)
Revenue
9.8% | 9.8%
EBITDA
21.0% | 25.1%
EBIT
21.8% | 17.7%
Net Income
37.2% | 14.4%
Free Cash Flow
28.3%
Margin (TTM | estimate)
Gross
59.3%
EBITDA
33.6% | 38.3%
EBIT
32.8%
Net
27.2% | 28.4%
Free Cash Flow
32.1%
Financial Health
Equity Ratio
73.0%
Return on Equity
23.5%
ROCE
23.6%
ROIC
22.0%
Debt/Equity
0.1
More
EPS
$9.5
FCF per Share
$11.3
Short interest
7.0%
Employees
10k
Rev per Employee
$520.0k
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a ResMed forecast:

15x Buy
68%
6x Hold
27%
1x Sell
5%

Analyst Opinions

22 Analysts have issued a ResMed forecast:

Buy
68%
Hold
27%
Sell
5%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,146 5,146
10% 10%
100%
- Direct Costs 2,093 2,093
3% 3%
41%
3,053 3,053
15% 15%
59%
- Selling and Administrative Expenses 991 991
8% 8%
19%
- Research and Development Expense 331 331
8% 8%
6%
1,731 1,731
21% 21%
34%
- Depreciation and Amortization 45 45
3% 3%
1%
EBIT (Operating Income) EBIT 1,686 1,686
22% 22%
33%
Net Profit 1,401 1,401
37% 37%
27%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Neutral
GlobeNewsWire
6 days ago
SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may al...
Neutral
Seeking Alpha
22 days ago
ResMed Inc. (NYSE:RMD ) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDT Company Participants Michael Farrell - CEO & Chairman Carlos Nunez - Chief Medical Officer Conference Call Participants Lyanne Harrison - BofA Securities, Research Division Presentation Lyanne Harrison BofA Securities, Research Division Good afternoon, everybody. My name is Lyanne Harrison.
Neutral
GlobeNewsWire
29 days ago
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London.
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today